The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Scholar Rock ...

Two studies were conducted to verify concerns about diabetic retinopathy that were raised during initial trials of ...

Recent research suggests a possible increased risk of serious eye conditions, such as non-arteritic anterior ischaemic optic ...

New studies indicate that weight-loss drugs may lead to serious eye diseases and vision loss in some individuals, prompting ...

Study links weight-loss drugs to serious eye conditions and vision loss - Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye co ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

The Government has announced a pilot to test new ways to support patients living with obesity, in a bid to ease pressures on ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Tirzepatide, an injection medication already approved by the Food and Drug Administration (FDA) to treat Type 2 diabetes, is likely to receive FDA approval for another indication — weight loss ...